Isodiol International Inc ISOLF

Reasoning behind the FDA strict stance on CBD

[heavymomentum]

Table 1.

Analysis of Dutch cannabis oil samples obtained from actual patients, comparing the claimed cannabinoid content on the product label with lab results measured in the study [51]

The highest order of testing must be established to protect consumers from companies that advertise harmful products and defraud the public that in turn can disrupt the homeostasis of the human body. This is (at a minimum) a required standard of an active pharmaceutical ingredient (API) in conjunction with medicines and healthcare products regulatory agency (MHRA) standards must be instituted among other standardised testing methods.

https://www.karger.com/Article/FullText/489287